Robust EM Continual Reassessment Method in Oncology Dose Finding
From MaRDI portal
Publication:3111177
DOI10.1198/jasa.2011.ap09476zbMath1229.62149OpenAlexW2041369657WikidataQ41545765 ScholiaQ41545765MaRDI QIDQ3111177
Publication date: 18 January 2012
Published in: Journal of the American Statistical Association (Search for Journal in Brave)
Full work available at URL: http://europepmc.org/articles/pmc3286608
model selectionmissing dataexpectation-maximization algorithmadaptive designmodel averagingmaximum tolerated doselate-onset toxicity
Lua error in Module:PublicationMSCList at line 37: attempt to index local 'msc_result' (a nil value).
Related Items (6)
Review of Statistical Treatment for Oncology Dose-Escalation Trial with Prolonged Evaluation Window or Fast Enrollment ⋮ Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial ⋮ Application of gamma process to two-agent combinations with delayed toxicity ⋮ A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes ⋮ Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity ⋮ Adaptive clinical trial designs for phase I cancer studies
This page was built for publication: Robust EM Continual Reassessment Method in Oncology Dose Finding
